Hansoh Pharma H1 Net Profit RMB4.258B, Up 35.82%; Interim Dividend 28.5 HK Cents
Hansoh Pharmaceutical reported a 35.82% year-on-year increase in interim net profit attributable to shareholders, reaching RMB4.258 billion for the six months ended June 30. Revenue rose 11.71% to RMB8.304 billion, with innovative drug sales up about 15.4% to RMB7.092 billion. The company declared an interim dividend of 28.5 HK cents, up 23.06% from the prior year. R&D spending grew 20.7% to RMB1.739 billion, supporting pipeline expansion and regulatory filings.
Hansoh Pharmaceutical announced its interim results for the six months ended June 30, with net profit attributable to shareholders reaching RMB4.258 billion, up 35.82% year on year. Basic earnings per share stood at RMB0.70, and the company declared an interim dividend of 28.5 HK cents, an increase of 23.06% from the previous year.
During the period, revenue rose 11.71% to RMB8.304 billion, of which innovative drug revenue amounted to approximately RMB7.092 billion, up about 15.4%. Research and development expenditure reached approximately RMB1.739 billion, an increase of 20.7%.
The company stated that in the second half of the year, it will continue to increase R&D investment, advance its innovative pipeline in oncology and non-oncology areas, and focus on new targets and technology platforms while expanding new indications. The group will accelerate clinical development and registration processes, plan to present key clinical study data at international academic conferences and in authoritative journals, and will submit new drug applications at appropriate times.